Weiguang Biological: plans to increase capital to its subordinate single plasma collection station by 55 million yuan.

Weiguang Biology announced that the sixth meeting of the fourth session of the Board of Directors approved an increase in capital of 15 million yuan and 40 million yuan for its subsidiaries, Wanning Jiang Station and Ankang Jiang Station, respectively, in cash, without the need for shareholder approval, not classified as a major asset restructuring or related party transaction. Wanning Jiang Station is a wholly-owned subsidiary of the company, and Ankang Jiang Station has an 80% stake, with the other shareholder, Xia Yuzhen, waiving the capital increase. After the capital increase, the registered capital of Wanning Jiang Station will increase to 20 million yuan, with the company holding 100% of the shares; Ankang Jiang Station's registered capital will increase to 11.9742 million yuan, with the company holding 91.65% of the shares. This capital increase is for the purpose of accelerating the construction of the Jiang stations and will not affect the scope of consolidated financial statements or the company's normal operations.